Minneapolis, Minnesota-based VTI (Vertebral Technologies, Inc.) is announcing a partnership with the Turkish medical distribution company Medikon to distribute its InterFuse product line in Turkey.
VTI Partners With Medikon for Turkish Distribution

“We are excited to start working with Medikon, the company has been serving the Turkish spine surgeon community since 1995 with highly differentiated products and I’m convinced they will do an excellent job selling the InterFuse product line,” said VTI’s Vice President of International Sales Ben Wasscher, in the May 4, 2017 news release.
Sinan Kazmaci, Managing Director of Medikon stated, “At Medikon we are excited to be working with the InterFuse modular cage. When we presented the product to our most important surgeons, there was a great deal of enthusiasm and excitement for the product. Surgeons thought that the modular approach to achieve a large footprint through a small access channel was a great idea and many of them are keen to start with InterFuse, especially for their more challenging patients.”
Ben Wasscher told OTW, “It is VTI’s objective to bring the benefits of the InterFuse modular cage, its large footprint and minimally invasive approach, to the largest number of patients. Turkey has a sizeable population and a well-developed health care sector. Our discussions with Turkish surgeons clearly demonstrated that they are certainly keen to use InterFuse with their patients.”
“Turkey is a country with around 80 million people. Initially the focus will be on the leading hospitals in Istanbul, but we anticipate expanding beyond that in the near future.”
Asked what might be challenging, he noted, “The reimbursement situation will certainly present challenges. But we are confident that together with our local partner Medikon, we can overcome these.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.